PAM
GYRE icon

PVG Asset Management’s Gyre Therapeutics GYRE Stock Holding History

PVG Asset Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,657
Closed -$283K – 74
2019
Q1 		$283K Buy
+4,657
New +$299K 0.25% 55

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

PVG Asset Management's GYRE Position: Q2 2019 in Review

PVG Asset Management sold out of Gyre Therapeutics (GYRE) in Q2 2019, closing a stake of 4,657 shares — an estimated $283K sold.

PVG Asset Management first reported a position in GYRE in Q1 2019 and held it in 1 quarter. The position peaked at $283K in Q1 2019. 49 funds tracked by Wall St. Rank hold GYRE as of Q2 2019.

  • PVG Asset Management reported no remaining Gyre Therapeutics position as of Q2 2019 after selling out during the quarter.
  • PVG Asset Management sold 4,657 Gyre Therapeutics shares in Q2 2019, an estimated $283K.
  • PVG Asset Management first reported a position in Gyre Therapeutics in Q1 2019 and held it in 1 quarter.
  • PVG Asset Management's Gyre Therapeutics position peaked at $283K in Q1 2019.
  • 49 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2019.

Based on PVG Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.